The activity of cefbuperazone against 266 
Cefbuperazone (BMY-25182; T-1982) is a new semisynthetic cephamycin antibiotic reported to have improved activity against resistant strains of aerobic, gram-negative bacteria and also to be active against anaerobic bacteria (12) . Regional differences in the susceptibility patterns of anaerobic bacteria and clustering of resistances at various hospitals have been noted and have led to the recommendation that susceptibility studies should be performed on selected clinical isolates (13) . Most clinical microbiology laboratories do not perform susceptibility tests on anaerobic bacteria. Due to the differences in patient populations and antibiotic usage, it is difficult to extrapolate data on the susceptibility of anaerobic bacteria performed at research and university hospitals (1-3, 5, 8, 9, 15) to those clinical situations encountered at community hospitals. Consequently, there are sparse data for the many community clinicians to make rational therapeutic decisions.
We compared the activity of cefbuperazone with that of cefoxitin, moxalactam, piperacillin, and clindamycin, drugs commonly used to treat anaerobic infections, against clinical anaerobic isolates from several community hospitals.
MATERIALS AND METHODS Organisms. The 266 strains of anaerobic bacteria used in this study (Tables 1 and 2) 
RESULTS
The results of the study are summarized in Tables 1 and 2.  Table 2 utilizes both high and low breakpoints for each drug (6, 13) . Isolates from both hospitals showed similar patterns of susceptibility and resistance. All of the agents tested showed excellent activity (>95% susceptible) against B. fragilis at both the high and low breakpoints. Cefbuperazone study showed cefbuperazone to have good activity against most anaerobic isolates. Its activity was comparable to that of cefoxitin against B. fragilis, Bacteroides vulgatus, Bacteroides spp., gram-positive cocci, and gram-negative, anaerobic cocci. Both cefoxitin and cefbuperazone showed poor activity against B. thetaiotaomicron, B. ovatus, and B. distasonis at the low breakpoint. However, cefoxitin was more active at the higher breakpoint (32 p.g/ml). Occasional strains showed high-level resistance (MIC, >128 ,ug/ml) to cefbuperazone, but not to cefoxitin. This suggests that the mechanism of resistance (i.e., poor penetration versus inactivation) may be different with these compounds (13) . With the exception of some strains of P. anaerobius, Clostridium clostridiiforme, C. innocuum, E. lentum, and Lactobacillus spp., cefbuperazone was active against all other anaerobic, gram-positive bacteria tested.
A recent study (13) (9, 11, 13, 14) . B. fragilis was our most frequent isolate, and it was usually susceptible to all agents. High-level resistance was seen primarily in B. thetaiotaomicron, B. ovatus, and B. distasonis isolates and only one strain of B. fragilis. The non-Bacteroides isolates, except for members of the genera Clostridium and Lactobacillus, were uniformly susceptible to all agents tested. It has been well documented that resistance is characteristic of those genera (9) (10) (11) .
Our data support the recommendation that published data on anaerobic susceptibility are not always reliable in choosing antimicrobial therapy (13) . We agree that all clinical microbiology laboratories, including those of community hospitals, need their own data base so that their physicians can make rational therapeutic choices. Indeed, even different types of hospitals in the same community may not be comparable.
